LIVE

BIAF

bioAffinity Technologies, Inc.

BIAF

NASDAQ·Healthcare·Medical - Diagnostics & Research·Mkt cap $3.8M

$0.83

-1.60%

View full research view

Our plain-language verdict, the thesis, risk factors, and what is changing about the business.

View research view

52-Week Range

$0.69 - $13.50

P/E

Fwd P/E

Beta

-1.33

Div Yield

0.00%

Avg Vol

629.7K

Shares Out

4.5M

Mkt Cap

$3.8M

Price action

Price chart

Down 90.3% over the trailing year

1W
1M
3M
6M
YTD
1Y
5Y
MAX

Total returns

Price performance

Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.

Why we rate it this way

The thesis at a glance

Bull and bear case · plain-English context across the five lenses we evaluate.

Bull Case

4 reasons

  • Proprietary non-invasive diagnostic technology
  • Early-stage cancer detection capabilities
  • Integrated diagnostic and therapeutic approach
  • Specialized focus on high-mortality cancer types

Bear Case

1 risk

  • Low volatility (beta -1.3).

Growth

Moderate growth ahead

Increasing lung cancer screening adoption and regulatory approvals

Value

Valuation data unavailable

Momentum

Falling

-78.5% over 3m

Quality

Stable

Below average quality

Dividend

None

No dividend

Earnings track record

Recent earnings results

AI-summarized recap of last quarter, plus the surprise on every print.

Next: May 20, 2026

Q2 26 RECAP

MAY 8, 2026

Reported EPS of -$0.81 vs -$2.40 consensus (+66.3% surprise). Revenue of $1.4M vs $1.5M expected (-8.9%).

EPS beat +66.3%
Revenue miss

EPS surprise · last 4Q

1 of 1 beats

Q2 26

+66.3%

Next: May 20, 2026

Revenue trend · last 8Q

-23%

-47%

-38%

-28%

-27%

Q2 24

Q3 24

Q4 24

Q1 25

Q2 25

Q3 25

Q4 25

Q1 26

$2.4M

$2.4M

$2.2M

$1.9M

$1.3M

$1.4M

$1.6M

$1.4M

Margins · last 8Q

Gross

Operating

Profit

-268.6%

Wall Street consensus

Analyst coverage

Live ratings and price targets aggregated across covering analysts.

No analyst coverage on file for this stock yet.

vs Industry

How BIAF stacks vs Medical - Diagnostics & Research

Stock metrics vs industry averages. Green = better than industry.

Industry comparison data unavailable for this stock.